Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Objective
The primary outcome is to compare five-year OS probabilities between the alloHCT cohort and an age and disease risk matched cohort of autoHCT patients. OS is calculated for all patients from the date of transplant until death from any cause. Observation is censored at the date of the last follow-up for patients alive at last contact.
Secondary outcomes: We will compare five-year PFS probabilities between the alloHCT cohort and an age and disease risk matched cohort of autoHCT patients. PFS is calculated as the interval from the date of transplant to the date of relapse/progression of MM or death from any cause, whichever comes first. Observation is censored at the date of last follow-up for patients alive without relapse/progression of MM at last contact.
